Basilea Pharmaceutica AG
BPMUF
$71.00
-$0.60-0.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 235.10M | 239.34M | 244.71M | 230.37M | 221.94M |
| Total Other Revenue | 46.37M | 37.07M | 27.87M | 21.38M | 15.63M |
| Total Revenue | 281.48M | 276.40M | 272.58M | 251.75M | 237.56M |
| Cost of Revenue | 176.11M | 160.86M | 146.23M | 136.93M | 131.73M |
| Gross Profit | 105.36M | 115.54M | 126.35M | 114.82M | 105.83M |
| SG&A Expenses | 42.16M | 40.07M | 38.13M | 36.13M | 35.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.28M | 200.93M | 184.37M | 173.06M | 166.98M |
| Operating Income | 63.20M | 75.47M | 88.22M | 78.70M | 70.58M |
| Income Before Tax | 55.67M | 69.21M | 83.22M | 75.55M | 68.98M |
| Income Tax Expenses | 6.74M | 3.19M | -381.00K | -9.94M | -19.58M |
| Earnings from Continuing Operations | 48.94 | 66.01 | 83.61 | 85.49 | 88.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.94M | 66.01M | 83.61M | 85.49M | 88.56M |
| EBIT | 63.20M | 75.47M | 88.22M | 78.70M | 70.58M |
| EBITDA | 66.46M | 78.60M | 91.23M | 81.64M | 73.48M |
| EPS Basic | 4.00 | 5.43 | 6.89 | 7.07 | 7.33 |
| Normalized Basic EPS | 2.84 | 3.55 | 4.29 | 3.90 | 3.57 |
| EPS Diluted | 3.83 | 5.04 | 6.29 | 6.48 | 6.70 |
| Normalized Diluted EPS | 2.55 | 3.14 | 3.75 | 3.42 | 3.12 |
| Average Basic Shares Outstanding | 48.96M | 48.82M | 48.67M | 48.46M | 48.31M |
| Average Diluted Shares Outstanding | 54.74M | 55.11M | 55.47M | 54.48M | 54.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |